PDGFRB and hepatocellular carcinoma: Sorafenib, a multikinase inhibitor that targets several serine/threonine and receptor tyrosine kinases including Raf, Vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptors (PDGFR), is the current standard of care for patients with advanced hepatocellular carcinoma (HCC) [2, 3].